HIV prevention videogame
BehavioralAssess acceptability and efficacy of a HIV prevention videogame
NCT Number: NCT02812329
This study aims to minimize risk of human immunodeficiency virus (HIV) in adolescent boys and girls, ages 15-16, by promoting HIV testing and counseling (HTC) through the use of an interactive videogame. With input from focus groups of adolescents, the investigators will adapt an HIV prevention videogame, PlayForward: Elm City Stories, for adolescents ages 15-16 . The investigators will then pilot test the videogame in 30 adolescents to assess the acceptability and feasibility of the videogame. They will also assess whether the videogame increased the participants' intentions to obtain HTC, whether they actually obtained HTC, and whether the videogame increased knowledge of HIV.
Looking for future studies?
Notify Me15 year–16 year
All sexes
Interventional
Phase 1
Adolescents are at high risk of contracting human immunodeficiency virus (HIV). To help them to minimize their risk and maintain their uninfected status, it is critical to give them the information, motivation, and skills to get HIV testing and counseling (HTC).
The current proposal focuses on adapting an existing HIV prevention videogame, PlayForward: Elm City Stories (R01HD062080), developed for 11-14 year olds, to include a primary focus on promoting access to and uptake of HTC in adolescent boys and girls, ages 15-16. PlayForward, an engaging and interactive videogame grounded in social learning theory and the theory of planned behavior, was developed through extensive work with its target audience to focus on the delay of sexual initiation in young teens and is currently demonstrating preliminary efficacy in a large randomized controlled trial (RCT).
In this Phase I proposal, PlayForward will be adapted for use in a slightly older age group with the primary outcome of encouraging them (increasing intentions) to obtain HTC and increasing knowledge about HIV/AIDS.
Working with the multi-disciplinary team of the play2PREVENT (p2P) Lab, we will conduct the formative work with our target audience and content experts to modify PlayForward for a focus on promoting HTC. To this end, our specific aims for this Phase I proposal targeting HTC in 15-16 year old adolescents are to:
Aim 1: Translate our culturally and socially-tailored videogame PlayForward to focus on HTC in an older age group of 15-16 year old boys and girls by:
Aim 2: Modify aspects of the PlayForward game to reflect this new focus by pilot testing it with 30 adolescents, aged 15-16 to determine in a pre-post design:
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
-
Assess acceptability and efficacy of a HIV prevention videogame
Time frame: After 3 weeks of using the videogame
Efficacy measure will include items on intentions around HIV Testing/Counseling and knowledge of HIV.
Time frame: Three weeks after 3 weeks of using the videogame
Efficacy measure will include items on intentions around HIV Testing/Counseling and knowledge of HIV.
Time frame: After 3 weeks of using the videogame
Yale University
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03823209
Acquired Immunodeficiency Syndrome, Blood-Borne Infections
Cleveland, Ohio, United States
View Trial DetailsNCT06176859
ART, Acquired Immunodeficiency Syndrome
Durban, KwaZulu-Natal, South Africa
View Trial DetailsNCT02344680
Acquired Immunodeficiency Syndrome, Adenocarcinoma
Lusaka, Lusaka Province, Zambia
View Trial DetailsNCT04704336
Acquired Immunodeficiency Syndrome, Blood-Borne Infections
St Louis, Missouri, United States
View Trial Details